TUMOR SUPPRESSION BY PARP INHIBITORS IS POTENTIATED BY c-MET INHIBITION

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2016年 / 6卷 / 03期
关键词：
D O I：
10.1158/2159-8290.CD-RW2016-017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：229 / 229
页数：1
相关论文
共 50 条
  • [31] Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition
    Damghani, Tahereh
    Elyasi, Maryam
    Pirhadi, Somayeh
    Haghighijoo, Zahra
    Ghazi, Somayeh
    MOLECULAR DIVERSITY, 2022, 26 (03) : 1411 - 1423
  • [32] C-Met inhibition sensitivity in vitro: Autocrine vs. paracrine activation of the c-Met pathway
    Hughes, Veronica
    Siemann, Dietmar W.
    CANCER RESEARCH, 2015, 75
  • [33] Development of new c-Met inhibitors and application of corresponding multitarget tyrosine kinase inhibitors in tumor therapy
    Zeng, Xiangcong
    Hu, Yuanwen
    Xu, Zhi
    Wu, Xiaoyu
    Xiong, Yun
    Liu, Shengpeng
    SOFT COMPUTING, 2023,
  • [34] Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer
    Chu, Yu-Yi
    Yam, Clinton
    Chen, Mei-Kuang
    Chan, Li-Chuan
    Xiao, Min
    Wei, Yong-Kun
    Yamaguchi, Hirohito
    Lee, Pei-Chih
    Han, Ye
    Nie, Lei
    Sun, Xian
    Moulder, Stacy L.
    Hess, Kenneth R.
    Wang, Bin
    Hsu, Jennifer L.
    Hortobagyi, Gabriel N.
    Litton, Jennifer
    Chang, Jeffrey T.
    Hung, Mien-Chie
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (02): : 648 - 661
  • [35] HGF/c-Met Signalling in the Tumor Microenvironment
    Zambelli, Alberto
    Biamonti, Giuseppe
    Amato, Angela
    TUMOR MICROENVIRONMENT: SIGNALING PATHWAYS, PT B, 2021, 1270 : 31 - 44
  • [36] MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors
    Jardim, Denis L. F.
    Gagliato, Debora de Melo
    Falchook, Gerald
    Zinner, Ralph
    Wheler, Jennifer J.
    Janku, Filip
    Subbiah, Vivek
    Piha-Paul, Sarina A.
    Fu, Siqing
    Tannir, Nizar
    Corn, Paul
    Tang, Chad
    Hess, Kenneth
    Roy-Chowdhuri, Sinchita
    Kurzrock, Razelle
    Meric-Bernstam, Funda
    Hong, David S.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : E19 - E26
  • [37] Combination of chemotherapy and c-MET inhibitors has synergistic effects in c-MET overexpressing pancreatic cancer cells
    Moosavi, Fatemeh
    Firoozi, Roya
    Tavakkoli, Marjan
    Nazari, Somayeh
    Alipour, Alireza
    Firuzi, Omidreza
    BIOCHIMIE, 2025, 231 : 73 - 83
  • [38] Autocrine c-met/HGF HCC patient derived xenograft (PDX) models for evaluating c-met inhibitors
    Chen, Dawei
    Song, Xiaoming
    Call, Jie
    Chen, Taiping
    Chen, Yiyou
    Li, Henry Q. X.
    CANCER RESEARCH, 2012, 72
  • [39] Optimization techniques for novel c-Met kinase inhibitors
    Sun, Zhi-Gang
    Yang, Yong-An
    Zhang, Zhi-Gang
    Zhu, Hai-Liang
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (01) : 59 - 69
  • [40] Recent Patents on the Development of c-Met Kinase Inhibitors
    Xu, Xiangming
    Yao, Lei
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2020, 15 (03) : 228 - 238
12345